Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Coadministration of 5% glucose solution has a decrease in bendamustine-related vascular pain grade.

Nakashima T, Ogawa Y, Kimura A, Kido M, Okikawa Y, Ito T, Hosokawa A, Kozawa K, Niimi H, Kiba T.

J Oncol Pharm Pract. 2012 Dec;18(4):445-7. doi: 10.1177/1078155212442560. No abstract available.

PMID:
22449716
3.

Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine.

Lim SH, Pathapati S, Langevin J, Hoot A.

Ann Hematol. 2012 Apr;91(4):643-4. doi: 10.1007/s00277-011-1307-z. No abstract available.

PMID:
21811782
4.

The emerging role of bendamustine in follicular lymphoma.

Friedberg JW.

Leuk Lymphoma. 2009 Mar;50(3):317-8. doi: 10.1080/10428190902741497. No abstract available.

PMID:
19347722
5.

Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect.

Malipatil B, Ganesan P, Sundersingh S, Sagar TG.

Hematol Oncol Stem Cell Ther. 2011;4(4):157-60. doi: 10.5144/1658-3876.2011.157.

6.

[II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].

Ogura M.

Gan To Kagaku Ryoho. 2012 May;39(5):736-42. Japanese. No abstract available.

PMID:
22701900
7.

HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.

Tsutsumi Y, Ogasawara R, Miyashita N, Tanaka J, Asaka M, Imamura M.

Int J Hematol. 2012 May;95(5):588-91. doi: 10.1007/s12185-012-1050-9. No abstract available.

PMID:
22419099
8.

Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53.

Sanchez-Gonzalez B, Garcia M, Serrano S, Besses C, Salar A.

Leuk Lymphoma. 2009 Mar;50(3):455-6. doi: 10.1080/10428190802684342. No abstract available.

PMID:
19263299
9.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD.

J Clin Oncol. 2011 Sep 1;29(25):3389-95. doi: 10.1200/JCO.2010.32.1844.

PMID:
21810687
10.

Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.

Hasegawa T, Aisa Y, Shimazaki K, Nakazato T.

Ann Hematol. 2015 Mar;94(3):515-7. doi: 10.1007/s00277-014-2182-1. No abstract available.

PMID:
25107463
11.

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Ogura M, Uchida T, Taniwaki M, Ando K, Watanabe T, Kasai M, Matsumoto Y, Shimizu D, Ogawa Y, Ohmachi K, Yokoyama H, Tobinai K; Japanese Bendamustine Lymphoma Study Group..

Cancer Sci. 2010 Sep;101(9):2054-8. doi: 10.1111/j.1349-7006.2010.01633.x.

12.

Stevens-Johnson syndrome after treatment with bendamustine.

Lambertini M, Del Mastro L, Gardin G, Levaggi A, Bighin C, Giraudi S, Pronzato P.

Leuk Res. 2012 Jul;36(7):e153-4. doi: 10.1016/j.leukres.2012.03.006. No abstract available.

PMID:
22480970
13.

Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).

Koenigsmann M, Knauf W, Herold M, Pasold R, Müller G, Eschenburg H, Kahl C, Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A.

Leuk Lymphoma. 2004 Sep;45(9):1821-7.

PMID:
15223642
14.

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K; Japanese Bendamustine Lymphoma Study Group..

Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x.

15.

Decrease in venous irritation by adjusting the concentration of injected bendamustine.

Watanabe H, Ikesue H, Tsujikawa T, Nagata K, Uchida M, Suetsugu K, Egashira N, Muta T, Kato K, Takenaka K, Ohga S, Matsushima T, Shiratsuchi M, Miyamoto T, Teshima T, Akashi K, Oishi R.

Biol Pharm Bull. 2013;36(4):574-8.

16.

Bendamustine can severely impair T-cell immunity against cytomegalovirus.

Hosoda T, Yokoyama A, Yoneda M, Yamamoto R, Ohashi K, Kagoo T, Ueno H, Boku S, Yano T.

Leuk Lymphoma. 2013 Jun;54(6):1327-8. doi: 10.3109/10428194.2012.739285. No abstract available.

PMID:
23072371
17.

Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.

Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, Arranz R, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A.

Leuk Res. 2012 Jun;36(6):709-14. doi: 10.1016/j.leukres.2011.10.024.

PMID:
22154023
18.

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.

Kath R, Blumenstengel K, Fricke HJ, Höffken K.

J Cancer Res Clin Oncol. 2001 Jan;127(1):48-54.

PMID:
11206271
19.

Bendamustine's emerging role in the management of lymphoid malignancies.

Rummel MJ, Gregory SA.

Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004. Review.

PMID:
21530769
20.

Blood and neoplastic diseases. Treatment of the lymphomas.

Fairley GH, Freeman JE.

Br Med J. 1974 Dec 28;4(5947):761-5. No abstract available.

Items per page

Supplemental Content

Support Center